Abstract Immunosuppressed organ transplant recipi-refractory leukaemia, or from infectious complications.
Introduction myelomonocytic leukaemia FAB M4 Eo (subtype according French-American-British criteria: acute The increased incidence of malignancy in immunomyelomonocytic leukaemia with an increase of eosinosuppressed organ transplant recipients (mostly renal phils). Cytogenetic analysis revealed an inversion of transplantations) has been documented in numerous the chromosome 16 (inv ( 16)). The renal transplant studies. The most frequent tumours are carcinomas of was functioning well. Creatinine was 1.3 mg/dl, blood the skin and the urogenital tract and malignant urea nitrogen ( BUN) 50 mg/dl, and the creatinine lymphomas. It is not clear whether the incidence of clearance 70 ml/min. acute leukaemia is also increased in comparison to the The patient received induction chemotherapy (cytarnormal population. Penn [1] observed a frequency of abine (100 mg/m2 on days 1+2 as continuous 2.3% of all types of leukaemia among all malignancies infusion+100 mg/m2 b.i.d. i.v. on days 3-8 ) and daureported to the Cincinnati Transplant Tumor Registry.
norubicin ( 60 mg/m2 i.v. on days 3-5 )), and complete However, these cases were not specified with regard to remission was documented on day 24 by bone marrow acute or chronic leukaemia and myeloid or lymphatic aspiration. Seven days after the end of the neutropenic origin. To our knowledge only eight case reports on phase the first consolidation chemotherapy consisting AML following renal transplantation have been pubof high-dose cytarabine (3000 mg/m2 b. (12 mg/m2 i.v. on days 3-5 ) instead of mitoxantrone was given. Filgrastim (recombinant human granulocyte allopurinol, and elimination of leukaemic blasts from circulation. colony-stimulating factor) (480 mg/day) was administered after every cycle. The duration of the neutropenic Now, 11 month after diagnosis of AML, the patient is in good health and continuing in complete remission. phases ( WBC <1 g/l ) was short after induction therapy (15 days) and first consolidation therapy (16 Renal function improved compared to status before chemotherapy (recent creatinine clearance 106 ml/min, days), but prolonged following the second consolidation therapy (31 days).
creatinine (serum) 0.9 mg/dl ). At present no further chemotherapy is planned. Immunosuppression was reduced before the start of chemotherapy. Azathioprine was discontinued. Prednisolone was temporarily discontinued, but reinDiscussion stated with 5 mg/day after the end of the neutropenic phases. Cyclosporin A was reduced to 50-75 mg/day to avoid accumulation due to interaction with itracona-Acute myeloid leukaemia in patients following renal transplantation leads to a difficult situation. Intensive zole and to maintain a serum level of approximately 80 ng/ml ( lower limit of the therapeutic range in our cytostatic treatment is needed to reduce the leukaemia load as much as possible and to give the organism a monoclonal assay). Antimicrobial prophylaxis and selective gut decontamination was performed with chance to control the leukaemic clone. Compared to other patients transplant recipients may be less capable co-trimoxazole (960 mg b.i.d.), colistine ( 200 mg t.i.d.), and itraconazole (200 mg t.i.d.). Fever of unknown to achieve this. However, these patients tolerate intensive treatment poorly due to fragile kidney funcorigin (>38°C ) occurred after induction and after the first consolidation therapy. It resolved in both cases tion and an increased risk of infections, including Pneumocystis carinii and invasive fungal infections. To under antibiotic therapy with piperacillin and tazobactam (4.5 g t.i.d.) within 5 and 3 days respectively. The our knowledge no case of successful therapy has been reported [2-9] (Table 1 ) . These discouraging results most serious infectious complication was pneumonia with 10 days of fever due to an unknown causative may suggest guarding against chemotherapy with a curative intent. However, our case shows that renal agent after the second consolidation therapy. Piperacillin/tazobactam ( 4.5 g t.i.d.) alone and in com-transplant patients may tolerate even a high-dose cytarabine therapy and a neutropenic phase of several bination with gentamicin (5 mg/kg/day) was not effective. A combination of teicoplanin (400 mg/day), weeks. The patient should be in a good performance status. Effective antibiotic and antimycotic prophylaxis erythromycin (4* 1 g/day) and imipenem/cilastin (1 g t.i.d.) led to complete regression of pneumonia.
and consistent therapy of infections are essential. Our patient showed an impairment of renal function In the first week after admission the patient developed a moderate impairment of renal function tightly correlated to rising WBC count before the start of chemotherapy. Major nephrotoxic side-effects by (increase in creatinine up to 2.4 mg/dl ). Renal function normalized following intensification of intravenous high-dose cytarabine, daunorubicin, idarubicin, and mitoxantrone have not been reported, and were not fluid load, alkalization of urine, administration of Induction and consolidation of acute myeloid leukaemia in a renal allograft recipient 595 observed in our patient. Therefore cytostatic therapy tion, intensive chemotherapy in patients with AML following renal transplantation in good performance should not be delayed when diagnosis is confirmed status is feasible. Although this may pose a threat to and appropriate hydratation and alkalization of urine the renal graft, our experience is that intensive chemoare provided.
therapy and maintenance of transplant function is not Continuation of immunosuppression is necessary as a contradiction. T-cell function may not be completely suppressed by cytostatic therapy. We monitored CsA serum Acknowledgements. M. Gorschlü ter was recipient of a grant from levels daily (monoclonal assay), since chemotherapy- 
